The company was founded as ChromaDex back in 2000 with the aim of researching and commercializing Niagen, which boosts levels of the compound nicotinamide adenine dinucleotide, or NAD in the human ...

There is a simple discount patient access scheme for leniolisib. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NHS organisations can contact ...

After considering the feedback from consultation, the evaluation committee has prepared final draft guidance (FDG) on leniolisib for activated phosphoinositide 3-kinase delta syndrome in people 12 ...